433 related articles for article (PubMed ID: 23649935)
41. National Control Laboratory Assessment of Quality of Rituximab Biosimilars in India.
Mishra NN; Sharma A; Shalini S; Sharma S; Jain P; Sharma RK; Chander H; Prasad JP; Anvikar AR; Chand S
Monoclon Antib Immunodiagn Immunother; 2022 Oct; 41(5):260-274. PubMed ID: 36306517
[TBL] [Abstract][Full Text] [Related]
42. Simultaneous Monitoring of Monoclonal Antibody Variants by Strong Cation-Exchange Chromatography Hyphenated to Mass Spectrometry to Assess Quality Attributes of Rituximab-Based Biotherapeutics.
Di Marco F; Berger T; Esser-Skala W; Rapp E; Regl C; Huber CG
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445776
[TBL] [Abstract][Full Text] [Related]
43. Identification and characterization of monoclonal antibody fragments cleaved at the complementarity determining region using orthogonal analytical methods.
Li W; Yang B; Zhou D; Xu J; Li W; Suen WC
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Mar; 1048():121-129. PubMed ID: 28242491
[TBL] [Abstract][Full Text] [Related]
44. Biosimilar or Not: Physicochemical and Biological Characterization of MabThera and Its Two Biosimilar Candidates.
Wang H; Wu L; Wang C; Xu J; Yin H; Guo H; Zheng L; Shao H; Chen G
ACS Pharmacol Transl Sci; 2021 Apr; 4(2):790-801. PubMed ID: 33860202
[TBL] [Abstract][Full Text] [Related]
45. Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method.
Kim H; Hong E; Lee J; Hong S; Kim J; Cho M; Kim Y; Yoo T
BioDrugs; 2023 Jul; 37(4):569-581. PubMed ID: 37060541
[TBL] [Abstract][Full Text] [Related]
46. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
Hermosilla J; Sánchez-Martín R; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Cuadros-Rodríguez L; Navas N
BioDrugs; 2019 Apr; 33(2):193-205. PubMed ID: 30875076
[TBL] [Abstract][Full Text] [Related]
47. Analytical and functional similarity of biosimilar ABP 798 with rituximab reference product.
Seo N; Huang Z; Kuhns S; Sweet H; Cao S; Wikström M; Liu J
Biologicals; 2020 Nov; 68():79-91. PubMed ID: 32888776
[TBL] [Abstract][Full Text] [Related]
48. Multiple-parallel-protease digestion coupled with high-resolution mass spectrometry: An approach towards comprehensive peptide mapping of therapeutic mAbs.
Pradhan G; Sneha JM; Sonwane BP; Santhakumari B; Rao A; Kulkarni MJ
J Proteomics; 2021 Feb; 232():104053. PubMed ID: 33238212
[TBL] [Abstract][Full Text] [Related]
49. Physicochemical Characterization, Glycosylation Pattern and Biosimilarity Assessment of the Fusion Protein Etanercept.
Montacir O; Montacir H; Springer A; Hinderlich S; Mahboudi F; Saadati A; Parr MK
Protein J; 2018 Apr; 37(2):164-179. PubMed ID: 29411222
[TBL] [Abstract][Full Text] [Related]
50. Assessment of structural and functional similarity of biosimilar products: Bevacizumab as a case study.
Bhattacharya S; Rathore AS
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Sep; 1229():123896. PubMed ID: 37776677
[TBL] [Abstract][Full Text] [Related]
51. Structural and Functional Analysis of CEX Fractions Collected from a Novel Avastin
Gurel B; Berksoz M; Capkin E; Parlar A; Pala MC; Ozkan A; Capan Y; Daglikoca DE; Yuce M
Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 36015197
[TBL] [Abstract][Full Text] [Related]
52. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles-Part 2: Mass spectrometric methods.
Reusch D; Haberger M; Falck D; Peter B; Maier B; Gassner J; Hook M; Wagner K; Bonnington L; Bulau P; Wuhrer M
MAbs; 2015; 7(4):732-42. PubMed ID: 25996192
[TBL] [Abstract][Full Text] [Related]
53. Screening of synthetic PDE-5 inhibitors and their analogues as adulterants: analytical techniques and challenges.
Patel DN; Li L; Kee CL; Ge X; Low MY; Koh HL
J Pharm Biomed Anal; 2014 Jan; 87():176-90. PubMed ID: 23721687
[TBL] [Abstract][Full Text] [Related]
54. Characterization of alanine to valine sequence variants in the Fc region of nivolumab biosimilar produced in Chinese hamster ovary cells.
Li Y; Fu T; Liu T; Guo H; Guo Q; Xu J; Zhang D; Qian W; Dai J; Li B; Guo Y; Hou S; Wang H
MAbs; 2016 Jul; 8(5):951-60. PubMed ID: 27050807
[TBL] [Abstract][Full Text] [Related]
55. Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®)).
Hofmann HP; Kronthaler U; Fritsch C; Grau R; Müller SO; Mayer R; Seidl A; Da Silva A
Expert Opin Biol Ther; 2016 Oct; 16(10):1185-95. PubMed ID: 27463856
[TBL] [Abstract][Full Text] [Related]
56. Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product.
Saleem R; Cantin G; Wikström M; Bolton G; Kuhns S; McBride HJ; Liu J
Pharm Res; 2020 May; 37(6):114. PubMed ID: 32476063
[TBL] [Abstract][Full Text] [Related]
57. Advanced assessment of the physicochemical characteristics of Remicade® and Inflectra® by sensitive LC/MS techniques.
Fang J; Doneanu C; Alley WR; Yu YQ; Beck A; Chen W
MAbs; 2016; 8(6):1021-34. PubMed ID: 27260215
[TBL] [Abstract][Full Text] [Related]
58. FcγRIIIA affinity chromatography complements conventional functional characterization of rituximab.
Narvekar A; Puranik A; Kulkarni B; Jagtap D; Jain R; Dandekar P
Biotechnol Prog; 2023 Jan; 39(1):e3304. PubMed ID: 36181372
[TBL] [Abstract][Full Text] [Related]
59. Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilars.
Kang J; Halseth T; Vallejo D; Najafabadi ZI; Sen KI; Ford M; Ruotolo BT; Schwendeman A
Anal Bioanal Chem; 2020 Jan; 412(3):763-775. PubMed ID: 31853605
[TBL] [Abstract][Full Text] [Related]
60. Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab).
Hong J; Lee Y; Lee C; Eo S; Kim S; Lee N; Park J; Park S; Seo D; Jeong M; Lee Y; Yeon S; Bou-Assaf G; Sosic Z; Zhang W; Jaquez O
MAbs; 2017; 9(2):364-382. PubMed ID: 28005456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
